Heron Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview

Heron Therapeutics

08/11/2024 15:45

* Heron Therapeutics Inc  HRTX.OQ   HRTX.O  is expected
to show a
rise in quarterly revenue when it reports  results on November
12 for the period ending September 30 2024
    * The San Diego California-based  company is expected to
report a
17.5% increase in revenue to $36.933 million from $31.43 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Heron Therapeutics Inc
is for
a loss of 3 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Heron
Therapeutics Inc is $7.00​, above​ its last closing price
of $1.77. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.04       -0.04      -0.06     Missed  -50
 Jan. 1 2024   -0.08       -0.09      -0.02     Beat    77.8
 Jan. 1 0001   -0.16       -0.16      -0.07     Beat    57.2​
 Sep. 30 2023  -0.29       -0.29      -0.17     Beat    41.9
 ​​Jun.        -0.23       -0.23      -0.35     Missed  -50
 30 2023                                                
 Mar. 31 2023  -0.21       -0.20      -0.27     Missed  -33​
 Dec. 31 2022  -0.30       -0.28      -0.17     Beat    40.4
 Jan. 1 0001   -0.38       -0.38      -0.38     Met     -1.1
 This summary was machine generated November 8 at 15:44 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)